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Fibrosis after solid organ transplantation is consid-
ered an irreversible process and remains the major
cause of graft dysfunction and death with limited
therapies. This remodeling is characterized by aber-
rant accumulation of contractile myofibroblasts that
deposit excessive extracellular matrix (ECM) and
increase tissue stiffness. Studies demonstrate, how-
ever, that a stiff ECM itself promotes fibroblast-to-
myofibroblast differentiation, stimulating further
ECM production. This creates a positive feedback
loop that perpetuates fibrosis. We hypothesized that
simultaneously targeting myofibroblast contractility
with relaxin and ECM stiffness with lysyl oxidase
inhibitors could break the feedback loop, reversing
established fibrosis. To test this, we used the ortho-
topic tracheal transplantation (OTT) mouse model,
which develops robust fibrotic airway remodeling.
Mice with established fibrosis were treated with sal-
ine, mono-, or combination therapies. Although
monotherapies had no effect, combining these
agents decreased collagen deposition and promoted
re-epithelialization of remodeled airways. Relaxin
inhibited myofibroblast differentiation and contrac-
tion in a matrix-stiffness–dependent manner through
prostaglandin E2 (PGE2). Furthermore, the effect of
combination therapy was lost in PGE2 receptor
knockout and PGE2-inhibited OTT mice. This study
revealed the important synergistic roles of cellular
contractility and tissue stiffness in the maintenance
of fibrotic tissue and suggests a new therapeutic
principle for fibrosis.
Abbreviations: BAPN, b-aminopropionitrile; Cntrl,
control; COX2, cyclooxygenase 2; CTCF, corrected
total cell fluorescence; DAPI, 40,6-diamidino-2-
phenylindole; DMEM, Dulbecco’s modified Eagle
medium; ECM, extracellular matrix; EP2, E prostanoid
2; IPF, idiopathic pulmonary fibrosis; LFA1, lympho-
cyte function-associated antigen 1; LGR7, leucine-rich
repeat–containing G protein-coupled receptor 7;
LOXL2, lysyl oxidase–like 2; LOX, lysyl oxidase; NS,
not significant; OTT, orthotopic tracheal transplanta-
tion; PBS, phosphate-buffered saline; PGE2, prosta-
glandin E2; pMLC, phospho–myosin light chain; Rlxn,
relaxin; RMST, root mean square tractions; RXFP1,
relaxin receptor 1; SEM, standard error of the mean;
a-SMA, a–smooth muscle actin
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Introduction
After tissue injury, the reparative response is character-
ized by a transient appearance of myofibroblasts that pro-
duce provisional, collagenous scars that protect against
further damage and rupture. In a normal response, the
provisional scars are eventually replaced by normal tis-
sue. In fibrosis, however, accumulation and activation of
myofibroblasts are persistent, resulting in overproduction
of stiff extracellular matrix (ECM) that replaces the nor-
mal tissue. Because few therapeutic options exist for
reversing fibrosis, this process may cause organ dysfunc-
tion and death. Previous studies have demonstrated that
the increased ECM stiffness that occurs in fibrosis is not
only a consequence of myofibroblast activation but also a
causative factor that independently perpetuates fibrosis
(1,2). The mechanical resistance of the ECM stimulates
myofibroblasts to express a–smooth muscle actin (a-
SMA), which enables cell contraction. This cellular con-
version then triggers the secretion and activation of
cytokines and growth factors, leading to additional ECM
production and creating a positive feedback loop (3).
Recent antifibrotic strategies targeting myofibroblast dif-
ferentiation and contraction have shown promising
results (4). Among these approaches is the use of
relaxin. Relaxin appears to inhibit fibrosis by attenuating
cellular contraction (5,6). Despite the lack of full under-
standing of its mechanisms of action, relaxin was tested
for the treatment of systemic sclerosis. An early placebo-
controlled trial showed that low-dose relaxin significantly
1229
© Copyright 2016 The American Society of Transplantation
and the American Society of Transplant Surgeons
doi: 10.1111/ajt.14103
American Journal of Transplantation 2017; 17: 1229–1241
Wiley Periodicals Inc.
reduced skin thickening and stabilized lung function (7).
Subsequent phase II and III trials, however, found no
significant benefit (8).
Other antifibrotic strategies have attempted to decrease
tissue stiffness by targeting collagen cross-linking, the
principal determinant of ECM stiffness. Lysyl oxidase
(LOX) is an enzyme that catalyzes the covalent cross-
linking of myofibroblast-secreted collagen units into
insoluble fibers (9). LOX is upregulated in fibrosis and is
associated with greater tissue stiffness in patients (10).
Animal studies have shown that inhibition of LOX and
LOX-like 2 (LOXL2) suppresses fibrosis in various organs
(11,12); however, clinical trials of LOXL2 inhibition were
terminated because of lack of efficacy.
Targeting myofibroblast contractility or ECM stiffness
individually has not yet been shown to be effective for
the treatment of human fibrotic disease, possibly
because both components are linked through a positive
feedback loop and likely require individualized drug
targeting. To address this possibility, we used the ortho-
topic tracheal transplantation (OTT) mouse model. Rejec-
tion of OTT allografts is characterized by the destruction
of the airway microvasculature and epithelial cell layer
followed by an accumulation of myofibroblasts that
deposit progressively cross-linked subepithelial collagen,
analogous to large airway changes seen in lung trans-
plantation (13); OTT mice do not develop bronchiolitis
obliterans. Evaluating changes in OTTs permits a detailed
physiologic and architectural assessment from which
careful inferences can be drawn concerning the process
of generalized fibrosis and fibrosis attenuation in large air-
ways. Unlike the fibrosis in the bleomycin lung injury
model, which is spontaneously reversible, the fibrosis in
OTTs is persistent and unresponsive to all immunomodu-
lating agents tested to date (14) and may model certain
intractable features of chronic lung allograft dysfunction.
In this study, we sought to determine whether targeting
both components of the biophysical microenvironment,
namely, myofibroblast contractility with relaxin and ECM
stiffness with LOX inhibition, could facilitate self-repair
and reduce fibrosis after “irreversible” tissue remodeling
was well established.
Materials and Methods
Animals and experimental procedures
Mice were acquired from the Jackson Laboratory (Bar Harbor, ME). Ani-
mal procedures were approved by the U.S. Department of Veterans
Affairs Palo Alto Health Care System institutional animal care and utiliza-
tion committee. OTTs were performed as described previously (15). In
short, tracheal segments from BALB/cJ (allograft) or C57BL/6J (syngraft)
donor mice were transplanted into C57BL/6J recipient mice (WT or
B6.126-Ptger2tm1Brey/J) on day 0. At 21 days after transplantation, mice
were treated with (i) saline, (ii) recombinant human relaxin-2 at 0.5 mg/
kg (Novartis Pharmaceutical) by continuous infusion with an Alzet mini
osmotic pump, (iii) 0.2% b-aminopropionitrile (BAPN; Sigma-Aldrich) in
drinking water, (iv) combination of recombinant human relaxin-2 at
0.5 mg/kg and 0.2% BAPN, or (5) combination of recombinant human
relaxin-2 at 0.5 mg/kg with anti-LOXL2 antibody at 0.5 mg/kg (Santa
Cruz Biotechnology) injected daily intraperitoneally on days 21–35. E
prostanoid 2 (EP2) selective antagonist PF-04418948 (Cayman Chemical)
was injected intraperitoneally daily at 10 mg/kg starting 21 days after
transplant, with or without relaxin and BAPN. Tracheas were harvested
after 14 days of treatment.
Cell culture
Fibroblasts from normal (line CCL-151; ATCC, Manassas, VA) and fibrotic
(line CCL-134; ATCC) human lungs were cultured in Dulbecco’s modified
Eagle medium (DMEM/F-12; Lonza) supplemented with 10% fetal bovine
serum, 100 U/mL penicillin, and 100 lg/mL streptomycin. Fibroblasts at
passages 2–5, cultured to <80% confluency, were seeded (4647 cells/
cm2) on collagen I–coated polyacrylamide gels (Matrigen) with elastic
moduli ranging from 0.5 to 25 kPa. Cells were treated with 1.2 mg/mL
recombinant human relaxin-2 with or without PF-04418948 at 10 lM in
DMEM/F-12 for 20 h after 4 h of serum starvation.
Immunofluorescent, picrosirius red, and Masson’s trichrome
staining
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Tri-
ton X-100 in phosphate-buffered saline (PBS) supplemented with 1%
bovine serum albumin, and immunostained after blocking. Mouse tra-
cheal tissues were fixed with 10% formalin, embedded in paraffin, then
cut cross-sectionally with a microtome (Leica Microsystems). The 8-lm
tracheal cross-sections were stained by immunofluorescent, picrosirius
red, or Masson’s trichrome staining. The following primary antibodies
were used: phospho–myosin light chain (pMLC) mAb (Cell Signaling Tech-
nology), pro–collagen type I mAb, cyclooxygenase 2 (COX2) mAb, leu-
cine-rich repeat–containing G protein-coupled receptor 7/relaxin receptor
1 (LGR7/RXFP1) polyclonal Ab (antibody; Abcam), and conjugated (Cy3) a-
SMA mAb (Sigma-Aldrich) at 1:200 dilution. For in vitro experiments, col-
lagen production was assessed by expression of procollagen I, a precur-
sor of collagen; fibroblast-to-myofibroblast differentiation was assessed
by a-SMA expression. The contraction of myofibroblasts was evaluated
and measured by immunofluorescent staining of pMLC and traction force
microscopy. Expressions of relaxin receptor on myofibroblasts were eval-
uated by immunofluorescent staining of RXFP1. Corrected total cell fluo-
rescence (CTCF) was measured by ImageJ (National Institutes of Health)
and defined as follows: CTCF = integrated density of selected cell(area
of selected cell 9 mean fluorescence of background readings). Antirabbit
Alexa Fluor 488, antirabbit Cy3, and antirat Cy3 were used for secondary
antibodies (Invitrogen).
Hydroxyproline assay
Mice tracheas were weighed, homogenized, and hydrolyzed in hydrochlo-
ric acid (12N). Hydroxyproline concentrations were measured according
to the manufacturer’s instructions (BioVision).
Immunosorbent assays and immunoblot analysis
For immunosorbent assays, supernatants were collected and PGE2 con-
centrations were detected by enzyme-linked immunosorbent assay,
according to the manufacturer’s instructions (Cayman Chemical). For
immunoblot analysis, cells were rinsed with PBS and lysed with radioim-
munoprecipitation assay buffer supplemented with Halt protease and
phosphatase inhibitor cocktail stabilized in dimethylsulfoxide (Thermo
Fisher Scientific). Cell lysates were loaded onto SDS-polyacrylamide gels
followed by electrophoresis and immunoblot analysis using chemilumi-
nescent immunodetection.
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Traction force microscopy
Traction generated by individual cells was measured as described previ-
ously (16). Cells were plated at 2 cells/mm2 on collagen-coated polyacry-
lamide gels embedded with fluorescent beads (0.5 lm). At 24 hours
later, a phase-contrast image and an image of the fluorescent beads
immediately underneath the cell were taken. The cells were detached
from the gels, and a second image of the same fluorescent beads was
taken. Displacement maps and traction fields were obtained by cross-
correlating these images.
Statistical analysis
The Shapiro–Wilk test was performed to test whether the data were nor-
mally distributed. Statistical significance (p < 0.05) was assessed using
the unpaired t-test assuming unequal variances between the treatment
and saline-control groups for hydroxyproline analysis (Prism Software). A
one-way analysis of variance test was used for the multiple group com-
parisons shown in Figure 5. For histologic analysis, at least 10 tissue sec-
tions from each animal (3–20 animals per group) were examined and
analyzed with the Mann–Whitney test. Analysis of collagen density in tri-
chrome-stained sections was measured by the ratio of the blue area to
the area between the subepithelium and cartilage with ImageJ. For
in vitro studies, results are from at least three independent experiments,
and statistical significance (p < 0.05) was assessed using the Mann–
Whitney test.
Results
Combined treatment with relaxin and LOX inhibition
attenuates established airway fibrosis
Previous studies showed that monotherapy with relaxin
or LOX inhibition is effective in preventing fibrosis in ani-
mal models (7,8). We assessed whether these drugs
could reverse the airway fibrosis in OTT recipients. Non-
immunosuppressed allograft OTT mice were treated at
21 days after transplantation, a time point at which fibro-
sis is well established (Figure S1). These mice were trea-
ted with relaxin, BAPN, LOXL2, relaxin with BAPN,
relaxin with LOXL2, or saline for 14 days (Figure 1A).
Relaxin monotherapy minimally decreased subepithelial
collagen deposition, whereas BAPN monotherapy had
no effect; however, combined relaxin and BAPN treat-
ment significantly diminished collagen deposition in the
subepithelial layer, as demonstrated by histology and
hydroxyproline concentration (Figures 1B–D). Moreover,
combined treatment with relaxin and BAPN promoted
tracheal re-epithelialization with taller cuboidal and pseu-
dostratified epithelium compared with animals in other
groups, which exhibited flattened epithelium (Figures 1B
and E). Substitution of BAPN with less toxic LOXL2 anti-
body in combined therapy modestly decreased subep-
ithelial collagen. There was a trend toward decreased
hydroxyproline concentration, but this did not meet
statistical significance (p = 0.0542) (Figure S2).
Decrease in cellular contractility with relaxin is
dependent on the type of fibroblast and matrix
stiffness
The in vivo data indicated that relaxin in combination with
LOX inhibition significantly decreased collagen deposition,
suggesting that the effectiveness of relaxin may be
dependent on ECM stiffness. Prior studies isolated the
role of matrix stiffness in cellular functions by plating cells
on inert cross-linked polyacrylamide hydrogels (17). The
effect of LOX inhibition in our study was modeled in vitro
by varying the stiffnesses of these matrices. This in vitro
model was used as a surrogate for BAPN because poly-
acrylamide gels allow one to isolate the contribution of
matrix stiffness, whereas a collagen matrix is limited by
the fact that plated cells can migrate into the matrix,
changing the stiffness. In addition, it should be noted that
because BAPN inhibits collagen cross-linking, it has no
action on a polyacrylamide gel.
One measure of stiffness is Young’s elastic modulus,
which is defined as the force per unit area (in pascals)
required to deform a given material. Shkumatov et al
measured the stiffness of intrapulmonary airways in the
mouse lung by atomic force microscopy and found that
the elastic moduli range from 2 to 45 kPa, with a median
of 18.6 kPa (18). In another study, Booth et al found that
the mean Young’s modulus of normal human lungs was
2 kPa, whereas that of tissue from idiopathic pulmonary
fibrotic lungs was 16 kPa (19). Consequently, we used
0.5- and 4-kPa matrices to mimic low lung tissue stiff-
ness and 12- and 25-kPa matrices to mimic intermediate
to high lung tissue stiffness.
On soft matrices (0.5 and 4 kPa), there was no detect-
able expression of procollagen I, a-SMA, or pMLC in nor-
mal lung fibroblasts (Figures S3 and 2A). On stiff
matrices (12 and 25 kPa), the expressions of procollagen
I (Figure S3), a-SMA, and pMLC (Figure 2A) were all sig-
nificantly increased. Relaxin inhibited expression of these
markers in normal lung fibroblasts plated on matrices
with intermediate stiffness (12 kPa) but not in cells
plated on the highest stiffness matrices (25 kPa)
(Figure 2A).
Lung fibroblasts from stiff conditions (i.e. fibrotic lung)
have been shown to be more contractile than those from
normal lungs (20). Consequently, we assessed whether
relaxin would regulate the contraction of fibrotic lung
fibroblasts and normal lung fibroblasts differently. We
found that fibrotic lung fibroblasts were more contractile
even with a relatively low matrix stiffness of 4 kPa (Fig-
ure 2B). At 4 kPa, relaxin was able to decrease the
expression of pMLC (Figure 2B). In contrast, on matrices
with intermediate and high stiffness, relaxin failed to
reduce pMLC expression. Immunoblots showed that in
normal lung fibroblasts, treatment with relaxin signifi-
cantly decreased pMLC expression at 12 kPa (Fig-
ure 2C), but in fibrotic lung fibroblasts, relaxin decreased
pMLC expression only at 4 kPa (Figure 2D).
To further examine relaxin’s effects on cell contraction,
we quantified the contractility of fibrotic and normal lung
fibroblasts by traction force microscopy (16). We found
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that both normal and fibrotic lung fibroblasts exhibited
increased contractions with increasing substrate stiffness
as measured by root mean square tractions (RMSTs)
(Figure 3). Treatment with relaxin decreased the contrac-
tion of normal lung fibroblasts plated on 12-kPa matrices
but had no significant effects on cells plated on matrices
with more stiffness (Figures 3A and C). Treatment with
relaxin decreased the contraction of fibrotic lung fibrob-
lasts plated on 4-kPa matrices but had no effects on cells
plated on matrices with elastic moduli of ≥12 kPa (Fig-
ures 3B and D).
Expression of RXFP1 on fibroblasts is modulated in
response to increases in matrix stiffness
Tan et al found that RXFP1 is significantly decreased in
the lungs of idiopathic pulmonary fibrosis (IPF) patients
and suggested that progression of IPF may be associ-
ated with sequential decreases of RXFP1 expression
(21). In our study, because relaxin’s positive effects were
dampened by a stiff microenvironment in vitro, we spec-
ulated that the expression of RXFP1 would be modulated
by a progressive increase in ECM stiffness. We found
that expression levels of RXFP1 were significantly higher
on fibroblasts plated on soft matrices (0.5 and 4 kPa)
than those on fibroblasts cultured on intermediate and
stiff matrices (12 and 25 kPa) (Figures 4A and C). Inter-
estingly, cells that expressed higher levels of a-SMA had
lower RXFP1 expression (Figure 4A) than cells express-
ing lower or nondetectable levels of a-SMA. Fibrotic lung
fibroblasts had much lower expression of RXFP1 than
normal lung fibroblasts. Expression levels of RXFP1 were
significantly decreased on fibrotic lung fibroblasts plated
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Figure 1: Combined treatment with relaxin and lysyl oxidase (LOX) inhibition attenuates established fibrosis in the ortho-
topic tracheal transplantation (OTT) model. Tracheal segments from donor mice were transplanted orthotopically into
MHC-matched (syngraft) or mismatched (allograft) recipient mice on day 0. (A) Nonimmunosuppressed OTT mice were subjected to
treatment at day 21, when fibrosis is well established, for 14 days. Mice were treated with recombinant human relaxin-2 or saline, with or
without the LOX inhibitor 0.2% b-aminopropionitrile (BAPN). (B) Representative images of Masson’s trichrome staining of tracheal
cross-sections in which collagen was stained in blue. Scale bar = 50 lm. (C) Hydroxyproline concentration in tracheal hydrolysates
relative to controls was measured to assess the amount of collagen; mean plus or minus standard deviation. (D) Analysis of collagen
density in trichrome stained sections measured by the ratio of the blue area to the area between the subepithelium and cartilage
with ImageJ; mean plus or minus standard error of the mean (SEM). (E) Measurement of epithelial thickness in tracheal cross-sections
from different groups; mean  SEM. *p < 0.05. For (B), (D), and (E), n = 3–10 per group with at least 10 tissue sections per animal.
NS, not significant.
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on matrices with elastic moduli of ≥4 kPa (Figures 4B
and D).
Combined relaxin and LOX inhibition efficacy is
dependent on COX2/PGE2
Next, to address how relaxin may augment LOX inhibi-
tion, we evaluated PGE2, a key eicosanoid implicated in
lung fibrosis regulation. PGE2 is generated when COX2
catalyzes the oxidation of arachidonic acid, and it is the
predominant prostaglandin in the lung (22–24). PGE2
has been shown to decrease cell contractility, and
levels of COX2/PGE2 are significantly decreased in lung
fibroblasts (22,25). This led us to investigate whether
the effectiveness of combined relaxin and BAPN
therapy was mediated through the COX2/PGE2 path-
way.
Mouse tracheal allografts of saline control, relaxin
monotherapy, and BAPN monotherapy groups had negli-
gible levels of COX2 expression (Figure 5A). By distinc-
tion, tracheas from mice treated with both relaxin and
BAPN demonstrated levels of COX2 expression in the
epithelium and subepithelium similar to that of tissue
from syngrafts. Next, we assessed the expression of
COX2 in normal lung fibroblasts on substrates with elas-
tic moduli ranging from 0.5 to 25 kPa. Cells plated on
stiff matrices had less COX2 expression than those pla-
ted on soft matrices, verifying previous observations (1).
Relaxin increased COX2 content in cells from 0.5- and 4-
kPa matrices but not from 12- or 25-kPa matrices (Fig-
ure 5B). Supernatants of fibroblasts plated on matrices
of physiological stiffness (0.5, 1, and 2 kPa) had higher
concentrations of PGE2 than those of cells plated on stif-
fer matrices (4, 12, and 25 kPa). Relaxin increased PGE2
levels on all but the stiffest matrices (25 kPa) (Fig-
ure 5C).
PGE2 can ligate four distinct G protein–coupled recep-
tors, termed EP receptors 1–4. Numerous reports have
implicated EP2 as the major receptor mediating inhibitory
effects on indices of fibroblast activation (26,27). To con-
firm that relaxin mediates a decrease in cell contraction
by upregulating COX2/PGE2 production and signaling via
the EP2 receptor, we inhibited the actions of PGE2 by
treating normal lung fibroblasts with PF-04418948, a
potent and selective EP2 antagonist. This EP2 antagonist
prevented the relaxin-mediated reduction of pMLC and
a-SMA in cells cultured on the 12-kPa matrices (Fig-
ure 6A).
To test whether the beneficial effects of the combined
treatment of relaxin and BAPN in vivo could be
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Figure 2: Decrease in cellular contractility with relaxin is dependent on the type of fibroblast and matrix stiffness. Immunoflu-
orescent staining and immunoblot analysis of normal and fibrotic lung fibroblasts. All results are from at least three independent exper-
iments. (A and B) Immunofluorescent staining of normal (A) and fibrotic (B) lung fibroblasts cultured on matrices with Young’s elastic
moduli of 0.5–25 kPa with and without relaxin. The contraction of cells was evaluated by expression of phospho–myosin light chain
(pMLC). Fibroblast-to-myofibroblast differentiation was assessed by a–smooth muscle actin (a-SMA) expression; scale bar = 424 lm.
(C and D) Immunoblot analysis of normal (C) and fibrotic (D) lung fibroblasts cultured on matrices with different elastic moduli. Cells
were treated without (Cntrl) or with relaxin (Rlxn). The graph represents quantification of the immunoblots by densitometry. Mean plus
or minus standard error of the mean. *p < 0.05. DAPI, 40,6-diamidino-2-phenylindole.
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abrogated by inhibition of the COX2/PGE2/EP2 pathway,
OTT mice at 21 days after transplantation were treated
with saline, PF-04418948, or combined relaxin and
BAPN treatment with or without PF-04418948. Further-
more, OTT EP2 receptor KO mice (B6.126-Ptger2
tm1Brey/
J) were treated with or without the combination of
relaxin and BAPN. Suppression of PGE2 signaling with
the EP2 receptor antagonist in the combined treatment
group abrogated the protective effect of combined treat-
ment, with specimens exhibiting dense deposition of
subepithelial collagen and no restoration of cuboidal
epithelium (Figures 6B and C). Similarly, treatment with
relaxin and BAPN lost its beneficial effects in EP2 KO
mice. Tracheas from PF-04418948–treated mice and
EP2 KO mice had higher amounts of collagen than
those from saline-treated control mice, as shown in
hydroxyproline concentration measurement. Combined
treatment of relaxin and BAPN failed to decrease colla-
gen amount in tracheas from PF-04418948–treated WT
and EP2 KO mice (Figures 6C and D), providing further
support that relaxin and BAPN act through the COX2/
PGE2/EP2 pathway.
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Discussion
Preclinical studies have used a large number of therapies
that have demonstrated the reversal of fibrosis in animal
models; however, very few have been found to be
effective in human fibrotic diseases. The discrepancy
between the preclinical and clinical findings may be
result in part from the use of models of fibrosis that
are not robust. Compared with other fibrotic models
such as the bleomycin-injured lung model, which is
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Figure 4: Expression of relaxin receptor 1 (RXFP1) on fibroblasts. (A and B) Immunofluorescent staining of RXFP1 on normal (A)
and fibrotic (B) lung fibroblasts cultured on matrices with Young’s elastic moduli of 0.5–25 kPa. Fibroblast-to-myofibroblast differentia-
tion was assessed by a-smooth muscle actin (a-SMA) expression; scale bar = 424 lm; inserts are 94 magnification of selected area.
(C and D) Corrected total cell fluorescence of normal (C) and fibrotic (D) lung fibroblasts cultured on matrices with different elastic
moduli (measured by ImageJ). Mean plus or minus standard error of the mean. n = 40–50 per group, *p < 0.05. DAPI, 40,6-diamidino-
2-phenylindole.
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spontaneously reversible, tissue remodeling in the OTT
model is particularly robust and progressive, driven
by inflammation (alloimmunity) not present in nontrans-
plant models of fibrosis. Treatment of the OTT model
with numerous immunosuppressant and antifibrotic
agents, including high-dose steroids, anti-CD40L, anti–
lymphocyte function-associated antigen 1 (anti-LFA1),
combined anti-CD40L/anti-LFA1 (14), and pirfenidone,
have not been able to reverse fibrosis (data not shown). In
this study, we demonstrated that combined therapy with
relaxin and LOX inhibition reversed established airway
fibrosis by targeting both intracellular and extracellular bio-
physical properties of the graft—cellular contractility and
ECM stiffness—and in this manner appeared to promote
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Figure 5: Relaxin induces cyclooxygenase 2 (COX2) and prostaglandin E2 (PGE2) in a stiffness-dependent manner.
(A) Immunofluorescent staining of tracheal cross-sections; scale bar = 212 lm; n = 3–10 per group with at least 10 tissue sections
per animal. (B) Immunoblots of normal lung fibroblast lysates. Cells were plated on matrices with different elastic moduli and were
treated without (Cntrl) and with relaxin (Rlxn); results were from at least three independent experiments. The graph represents quan-
tification of the immunoblot by densitometry; mean plus or minus standard error of the mean (SEM). (C) Normal human lung fibrob-
lasts were cultured on matrices with Young’s elastic moduli of 0.5, 1, 2, 4, 12, and 25 kPa and treated with or without relaxin.
Supernatants of cells were collected, and PGE2 concentrations were detected by PGE2 enzyme-linked immunosorbent assay;
mean  SEM. n = 5–10 per group. *p < 0.05. BAPN, b-aminopropionitrile; DAPI, 40,6-diamidino-2-phenylindole.
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packed fibers that increase extracellular matrix (ECM) stiffness. Fibrotic ECM stiffness may then activate cells to be more contractile,
leading to further collagen deposition. This positive feedback loop leads to persistent fibrosis and creates a pathological condition.
Relaxin upregulates cyclooxygenase 2 (COX2) and prostaglandin E2 (PGE2), decreasing cellular contraction, which in turn promotes
ECM softening. LOX inhibition downregulates collagen cross-linking, thereby decreasing ECM stiffness, which in turn decreases
myofibroblast contractility. This breaks the positive feedback loop and returns the tissue to a physiological condition. Furthermore,
COX2/PGE2 may contribute to further decrease collagen cross-linking and ECM softening through LOX inhibition. A soft ECM may also
increase COX2/PGE2, which in turn can decrease myofibroblast contractility. These mechanisms may further support the reversal of
fibrosis. a-SMA, a–smooth muscle actin; BAPN, b-aminopropionitrile; ECM, extracellular matrix; NS, not significant; PF, PF-04418948;
pMLC, phospho–myosin light chain; Rlxn, relaxin.
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the conversion toward a normal, nonremodeled, epithelial-
ized airway.
As described, myofibroblast activation and contraction
contribute to ECM stiffening and further fibrotic progres-
sion. Myofibroblast contractility is regulated by MLC
phosphorylation, which enables myosin to interact with
actin filaments to generate force. We found that pMLC
and RMST of lung fibroblasts cultured on matrices with
soft and intermediate stiffness were downregulated by
relaxin. Relaxin also decreased a-SMA and procollagen I
expression in normal lung fibroblasts on matrices with
soft or intermediate stiffness but lost its effects on very
stiff matrices. In the mouse OTT model, monotherapy
with relaxin had only a minimal effect in reversing fibro-
sis. Given the in vitro findings, we suspect that relaxin
alone was not effective in reversing fibrosis in the OTT
model (and possible fibrosis in human) because the ECM
of the tracheas was already very stiff.
Relaxin was first named for its ability to relax the female
reproductive tract during pregnancy (28). It is produced
by both sexes and has been shown to act intracellularly
to induce cellular relaxation and to ameliorate fibrosis
(29). Relaxin and its G protein–coupled receptors are
found in rodent and human lungs, predominantly within
bronchial epithelial cells, fibroblasts, and airway smooth
muscle cells (6,30). Intriguingly, relaxin-deficient mice
develop age-associated fibrosis in the lung and skin
(31,32). However, as stated earlier, phase II and III trials
of relaxin did not demonstrate any efficacy in the treat-
ment of fibrosis in systemic sclerosis (8). It has been
shown that RXFP1 level is decreased in lungs of IPF
patients (21). We found that fibroblasts that were plated
on stiff matrices had significantly lower RXFP1 expres-
sion than those plated on soft matrices. This may sug-
gest that expression of RXFP1 is associated with
progressive increase of ECM stiffness in fibrosis. Conse-
quently, we speculate that the lack of effect in estab-
lished dermal fibrosis may be due to the relatively high
tissue stiffness.
Tissue stiffening results mainly from the cross-linking of
ECM proteins (33). LOX converts collagen from soluble
monomers to insoluble fibers by oxidizing peptidyl lysine
to form covalent cross-linkages, thereby increasing ECM
stiffness (9). Inhibition of LOX with BAPN decreased a-
SMA expression and fibrotic tissue stiffness in a carbon
tetrachloride–induced liver fibrosis model. (11). In a bleo-
mycin lung model, inhibition of LOXL2 with a mono-
clonal antibody decreased collagen deposition (12).
Nevertheless, a clinical phase II trial was terminated
because of lack of efficacy. Intriguingly, the current
study modeled persistent alloimmune injury, and LOX
inhibitor monotherapy failed to reverse established fibro-
sis. We modeled the effect of LOX inhibition and iso-
lated the role of substrate stiffness by plating cells on
inert polyacrylamide gels with stiffnesses ranging from
normal to fibrotic tissues. We found that soft (0.5 and
4 kPa) but not intermediate or stiff (12 and 25 kPa) sub-
strates prevented expression of procollagen I and the
differentiation and contraction of fibroblasts. These find-
ings suggest that the chronically rejected trachea is
stiffer than normal airways (range 2–45 kPa (18)) and
exceeded the threshold below which the profibrotic
feedback loop could be interrupted by LOX inhibition
alone.
Fibrotic lungs express less COX-2/PGE2 than healthy
lungs (34). We found that allogeneic transplanted tra-
cheas have less COX2 and more a-SMA expression than
syngeneic transplants. Allografts from mice treated with
combined relaxin/LOX inhibition express more COX2 than
those from monotherapies. In vitro, relaxin upregulated
COX2 expression and PGE2 secretion in fibroblasts cul-
tured on soft matrices but not on stiff matrices. Relaxin
boosted the secretion of endogenous PGE2 from cells on
low- to intermediate-stiffness matrices but failed to
increase PGE2 levels in cells cultured on pathologically
stiff matrices (≥25 kPa). These results suggest that relax-
in’s ability to upregulate COX2/PGE2 is dampened by a
stiff microenvironment. This was also observed in
previous studies that demonstrated that a stiff ECM
suppresses the secretion of COX2/PGE2. Previous inves-
tigations showed that PGE2 signaling through the EP2
receptor inhibits lung myofibroblast differentiation, con-
traction, and secretion of collagen (26,35). We found that
treatment with an EP2 receptor antagonist abrogated the
effects of relaxin on cells cultured in the intermediate-
stiffness matrices and the beneficial effects of combined
treatment on fibrotic airways. These results cumulatively
indicate that the effectiveness of combined relaxin and
BAPN treatment in abrogating subepithelial fibrosis is
mediated through COX2 expression, PGE2 biosynthesis,
and EP2 signaling.
In addition to decreasing myofibroblast contractility
directly, PGE2 has also been shown to inhibit LOX (36),
which may contribute to further decrease in collagen
cross-linking and softening of the ECM. Moreover, Liu
et al demonstrated that a stiff ECM suppresses the
COX2/PGE2 pathway (1); therefore, decreasing collagen
cross-linking with LOX inhibition may lead to increased
COX2/PGE2, which in turn can decrease myofibroblast
contractility. These mechanisms may further support the
reversal of fibrosis (Figure 6E).
Combined treatment not only decreased subepithelial
fibrosis but also promoted an epithelium expressing a
high level of COX2. Konoeda et al showed that fibrosis
in the chronically rejected airways is associated with
an aberrant flattened epithelium, and the damage to
epithelial cells appears before subepithelial fibrosis (37).
In contrast to the flattened epithelium observed in
other treatment groups, mice treated with combined
therapy had taller, more cuboidal, and occasionally
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pseudostratified epithelial layers. Because the airway
epithelium is a major source of PGE2 (38), its damage
could lead to decreased levels of PGE2 in the airway and
an inability to inhibit fibroblast proliferation and activation,
thereby promoting subepithelial fibrosis. However, the
mechanism by which combined therapy with relaxin and
LOX inhibition contribute to the development of this
columnar epithelium requires further investigation. Prior
studies showed that PGE2 deficiency in lung fibrosis
leads to increased airway epithelial cell apoptosis, and PGE2
has been shown to promote epithelial cell proliferation and
migration (39,40). We speculate that the collagen-rich
subepithelium is unable to support a pseudostratified
columnar epithelium, perhaps in part because of a defi-
ciency of COX2/PGE2.
A limitation of this study is that we were unable to
confirm that LOX inhibition decreased tracheal stiffness
in vivo. We attempted to measure the elastic moduli
of the tracheas with atomic-force microscopy but found
wide variability within each sample, with point-to--point
differences up to 10 kPa (data not shown). Previous
studies have shown that Young’s elastic moduli of non-
cartilaginous lung airways range from 2 to 45 kPa (18).
We suspect that the variability in cartilaginous airways
will be even higher. Another limitation of this study is
that although BAPN is a potent irreversible inhibitor of
LOX, wider clinical use is limited by its side effects,
such as osteolethyrism, a disorder that can lead to
skeletal deformations (41). We replaced BAPN with
nontoxic LOXL2 antibody and found that the combined
treatment of relaxin and LOXL2 had a less significant
effect on reduction of collagen. BAPN was used in this
study as a proof of concept; for clinical use, other less
toxic and more potent LOX or LOX-like inhibitors in
conjunction with relaxin could be tested.
In summary, we demonstrated reversal of transplanted
airway fibrosis by targeting both intracellular and extracel-
lular biophysical properties of the allograft. We showed
that relaxin increases the expression of COX2/PGE2 and
thus decreases cellular contraction, whereas LOX inhibi-
tion decreases tissue stiffness; together, they may shift
the airway toward a physiological state (Figure 6E). The
reversal of established fibrosis achieved in this work may
represent a novel therapeutic strategy for the treatment
of chronic rejection in solid organ transplantation and
other fibrotic diseases.
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Figure S1. Airway fibrosis is established at day 21
after transplantation. (A, B) Representative images of
picrosirius red staining of tracheal cross-sections at days
21 and 35 after transplantation. Under bright field micro-
scopy, collagen is stained red. Under polarized light, large
and dense collagen bundles are visualized in orange and
yellow. (C) In tracheal sections from relaxin and b-amino-
propionitrile (BAPN)–treated mice, under polarized light,
thin and loose collagen fibers are visualized in green.
Scale bar = 50 lm.
Figure S2. Combined treatment with relaxin and lysyl
oxidase–like 2 (LOXL2) inhibition attenuates estab-
lished fibrosis in orthotopic tracheal transplantation
(OTT) tracheas. (A) Representative images of Masson’s
trichrome staining of tracheal cross-sections in which col-
lagen was stained in blue. Scale bar = 50 lm; n = 3–10
per group with at least 10 tissue sections per animal.
(B) Analysis of collagen density in trichrome-stained sec-
tions measured by the ratio of the blue area to the area
between the subepithelium and cartilage; mean plus or
minus standard error of the mean; *p < 0.05. (C) Hydroxy-
proline concentration in tracheal hydrolysates relative to
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controls was measured to assess the amount of collagen.
Mean plus or minus standard deviation; p = 0.054.
Figure S3. Immunofluorescent staining of human
normal lung fibroblasts cultured with and without
relaxin on matrices with Young’s elastic moduli of
0.5, 4, 12, and 25 kPa. Collagen production was assessed
by expression of procollagen I; fibroblast-to-myofibroblast
differentiation was assessed by a–smooth muscle actin
(a-SMA) expression. Results are from at least three inde-
pendent experiments; scale bar = 848 lm.
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